Compare Stocks: CTXR, ELOX, HRTX, and INCR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.56 0.0%	$0.59	$0.47 ▼ $2.19	$15.37M	1	595,415 shs	139,286 shs
ELOX Eloxx Pharmaceuticals	$17.63 -3.4%	$15.58	$8.20 ▼ $23.40	$71.16M	-1862.26	52,173 shs	17,999 shs
HRTX Heron Therapeutics	$0.32 +1.2%	$0.39	$0.30 ▼ $1.58	$60.33M	1.61	2.50 million shs	1.10 million shs
INCR InterCure	$5.31 +3.5%	$4.98	$3.40 ▼ $8.45	$58.09M	1.42	15,344 shs	2,505 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	-2.27%	-6.73%	-25.87%	+3.72%	-50.87%
ELOX Eloxx Pharmaceuticals	+11.96%	+12.86%	-2.72%	+30.36%	+150,726.45%
HRTX Heron Therapeutics	-0.41%	-10.29%	-6.74%	-18.93%	-74.68%
INCR InterCure	-3.02%	-4.82%	+6.88%	+9.28%	-33.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTXR Citius Pharmaceuticals	$0.56 0.0%	$0.59	$0.47 ▼ $2.19	$15.37M	1	595,415 shs	139,286 shs
ELOX Eloxx Pharmaceuticals	$17.63 -3.4%	$15.58	$8.20 ▼ $23.40	$71.16M	-1862.26	52,173 shs	17,999 shs
HRTX Heron Therapeutics	$0.32 +1.2%	$0.39	$0.30 ▼ $1.58	$60.33M	1.61	2.50 million shs	1.10 million shs
INCR InterCure	$5.31 +3.5%	$4.98	$3.40 ▼ $8.45	$58.09M	1.42	15,344 shs	2,505 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTXR Citius Pharmaceuticals	-2.27%	-6.73%	-25.87%	+3.72%	-50.87%
ELOX Eloxx Pharmaceuticals	+11.96%	+12.86%	-2.72%	+30.36%	+150,726.45%
HRTX Heron Therapeutics	-0.41%	-10.29%	-6.74%	-18.93%	-74.68%
INCR InterCure	-3.02%	-4.82%	+6.88%	+9.28%	-33.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTXR Citius Pharmaceuticals	2.40	Hold	$5.00	792.86% Upside
ELOX Eloxx Pharmaceuticals	2.75	Moderate Buy	$41.50	135.39% Upside
HRTX Heron Therapeutics	2.00	Hold	$2.00	529.33% Upside
INCR InterCure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest CTXR, ELOX, HRTX, and INCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/20/2026	ELOX Eloxx Pharmaceuticals	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	CTXR Citius Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/19/2026	CTXR Citius Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	ELOX Eloxx Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/11/2026	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/3/2026	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/22/2026	ELOX Eloxx Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$40.00
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/20/2026	ELOX Eloxx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/17/2026	HRTX Heron Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$4.29 per share	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	($85.17) per share	N/A
HRTX Heron Therapeutics	$154.90M	0.39	N/A	N/A	$0.07 per share	4.54
INCR InterCure	$78.47M	0.74	N/A	N/A	$10.53 per share	0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTXR Citius Pharmaceuticals	-$37.43M	-$1.67	N/A	N/A	N/A	N/A	-59.57%	-34.47%	N/A
ELOX Eloxx Pharmaceuticals	-$5.99M	-$1.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/3/2026 (Estimated)
INCR InterCure	-$10.37M	$0.15	35.40	N/A	N/A	N/A	N/A	N/A	N/A

Latest CTXR, ELOX, HRTX, and INCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTXR Citius Pharmaceuticals	-$0.36	-$0.34	+$0.02	-$0.34	$5.46 million	N/A
8/11/2026	Q2 2026	ELOX Eloxx Pharmaceuticals	N/A	-$0.66	N/A	-$0.66	N/A	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTXR Citius Pharmaceuticals	0.08	0.84	0.40
ELOX Eloxx Pharmaceuticals	N/A	3.74	3.74
HRTX Heron Therapeutics	24.35	2.49	1.51
INCR InterCure	0.20	1.48	0.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTXR Citius Pharmaceuticals	16.88%
ELOX Eloxx Pharmaceuticals	2.90%
HRTX Heron Therapeutics	80.01%
INCR InterCure	8.34%

Insider Ownership

Company	Insider Ownership
CTXR Citius Pharmaceuticals	4.99%
ELOX Eloxx Pharmaceuticals	25.90%
HRTX Heron Therapeutics	6.10%
INCR InterCure	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTXR Citius Pharmaceuticals	20	27.45 million	26.08 million	Optionable
ELOX Eloxx Pharmaceuticals	7	4.04 million	2.99 million	N/A
HRTX Heron Therapeutics	300	189.85 million	178.27 million	Optionable
INCR InterCure	350	10.94 million	N/A	Optionable

CTXR, ELOX, HRTX, and INCR Headlines

Recent News About These Companies

InterCure Regains Nasdaq Compliance After Delisting Warning

September 8, 2026 | tipranks.com

InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

September 8, 2026 | globenewswire.com

InterCure (INCR) Finalized a $77M Settlement, but How Much New Cash Will it Receive?

August 27, 2026 | insidermonkey.com

InterCure Raises $5 Million in August Private Placement to Rebuild Nir Oz Facility

August 26, 2026 | tipranks.com

InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages

August 24, 2026 | globenewswire.com

Intercure Ltd (INCR) Stock Price, Quote, News & History

August 20, 2026 | benzinga.com

InterCure Ltd. Announces 1-for-5 Reverse Share Split

August 19, 2026 | markets.businessinsider.com

InterCure Shareholders Approve Proposal at August 11 Extraordinary Meeting

August 11, 2026 | tipranks.com

What Is Driving InterCure (NASDAQ:INCR) on the Nasdaq?

July 23, 2026 | kalkinemedia.comK

InterCure Calls August 12 EGM to Approve 5‑for‑1 Reverse Share Split

July 22, 2026 | tipranks.com

InterCure Posts 2025 Revenue Growth, Positive Cash Flow as Recovery and Expansion Accelerate

July 8, 2026 | theglobeandmail.com

InterCure Secures NIS 22 Million Private Placement With Potential to Rise to NIS 54 Million for Global Expansion

June 22, 2026 | quiverquant.comQ

InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds

June 22, 2026 | globenewswire.com

InterCure Ltd. Completes First Tranche of Botanico Acquisition to Enhance International Medical Cannabis Platform

June 15, 2026 | quiverquant.comQ

InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition

June 15, 2026 | globenewswire.com

InterCure Ltd. Reports NIS 270 Million Revenue and Positive Cash Flow for 2025 Amid Recovery Efforts

April 30, 2026 | quiverquant.comQ

InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow

April 30, 2026 | globenewswire.com

InterCure Ltd: InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

March 4, 2026 | finanznachrichten.de

InterCure Ltd. Receives Nasdaq Compliance Notice Due to Bid Price Deficiency, Plans to Regain Compliance

March 3, 2026 | quiverquant.comQ

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

March 3, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTXR, ELOX, HRTX, and INCR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

$0.56 0.00 (-0.02%)

Closing price 04:00 PM Eastern

Extended Trading

$0.57 +0.01 (+1.07%)

As of 04:15 PM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Eloxx Pharmaceuticals NASDAQ:ELOX

$17.63 -0.62 (-3.40%)

As of 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Heron Therapeutics NASDAQ:HRTX

$0.32 +0.00 (+1.21%)

Closing price 04:00 PM Eastern

Extended Trading

$0.32 +0.00 (+0.06%)

As of 05:11 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

InterCure NASDAQ:INCR

$5.31 +0.18 (+3.51%)

Closing price 04:00 PM Eastern

Extended Trading

$5.32 +0.01 (+0.09%)

As of 04:49 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTXR, ELOX, HRTX, and INCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTXR, ELOX, HRTX, and INCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTXR, ELOX, HRTX, and INCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTXR, ELOX, HRTX, and INCR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Eloxx Pharmaceuticals NASDAQ:ELOX

Heron Therapeutics NASDAQ:HRTX

InterCure NASDAQ:INCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTXR, ELOX, HRTX, and INCR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTXR, ELOX, HRTX, and INCR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTXR, ELOX, HRTX, and INCR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTXR, ELOX, HRTX, and INCR Company Descriptions

Citius Pharmaceuticals NASDAQ:CTXR

Eloxx Pharmaceuticals NASDAQ:ELOX

Heron Therapeutics NASDAQ:HRTX

InterCure NASDAQ:INCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools